Lexeo Therapeutics (LXEO) EBIT (2022 - 2026)
Lexeo Therapeutics (LXEO) posted EBIT of -$22.3 million for Q1 2026, up 3.39% sequentially from -$23.1 million in Q4 2025, and up 33.94% YoY from -$16.7 million in Q1 2025.
Lexeo Therapeutics (LXEO) EBIT (2022 - 2026) Analysis & Trends
Lexeo Therapeutics has reported EBIT for 5 years, with the latest figure at -$22.3 million in Q1 2026.
- Quarterly EBIT rose 33.94% year-over-year to -$22.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$97.8 million (up 15.91% YoY) and the FY2025 annual result came in at -$109.3 million, down 3.3% from the prior year.
- EBIT climbed to -$22.3 million in Q1 2026 per LXEO's latest filing, from -$23.1 million in the prior quarter.
- Over five years, EBIT peaked at -$14.0 million in Q2 2023 and troughed at -$33.8 million in Q1 2025.
- A 5-year average of -$22.6 million and a median of -$22.3 million in 2026 frame the typical range for EBIT.
- The sharpest annual moves came in 2024 and 2026: EBIT plunged 82.86% in 2024, then surged 33.94% in 2026.
- Over 5 years, EBIT stood at -$15.2 million in 2022, then climbed by 1.47% to -$15.0 million in 2023, then slumped by 82.86% to -$27.4 million in 2024, then advanced by 15.58% to -$23.1 million in 2025, then rose by 3.39% to -$22.3 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$22.3 million, -$23.1 million, and -$21.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Lexeo Therapeutics | 397.10 Mn | 397.10 Mn | - | -28.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.02 Mn |
| Mar 31, 2026 | -22.33 Mn |
| Dec 31, 2025 | -23.12 Mn |
| Sep 30, 2025 | -21.65 Mn |
| Jun 30, 2025 | -30.69 Mn |
| Mar 31, 2025 | -33.81 Mn |
| Dec 31, 2024 | -27.38 Mn |
| Sep 30, 2024 | -31.54 Mn |
| Jun 30, 2024 | -23.55 Mn |
| Mar 31, 2024 | -23.29 Mn |
| Dec 31, 2023 | -14.97 Mn |
| Sep 30, 2023 | -20.27 Mn |
| Jun 30, 2023 | -13.98 Mn |
| Mar 31, 2023 | -19.29 Mn |
| Dec 31, 2022 | -15.20 Mn |
| Sep 30, 2022 | -17.48 Mn |